Last reviewed · How we verify
Apatinib and Etoposide capsule
Apatinib is a small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor 2 (VEGFR2), while Etoposide is a topoisomerase inhibitor that works by interfering with the enzyme topoisomerase II, thereby inhibiting DNA replication and transcription.
Apatinib is a small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor 2 (VEGFR2), while Etoposide is a topoisomerase inhibitor that works by interfering with the enzyme topoisomerase II, thereby inhibiting DNA replication and transcription. Used for Metastatic gastric cancer, Non-small cell lung cancer.
At a glance
| Generic name | Apatinib and Etoposide capsule |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | tyrosine kinase inhibitor, topoisomerase inhibitor |
| Target | VEGFR2, topoisomerase II |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Apatinib's mechanism of action involves the inhibition of VEGFR2, which is involved in angiogenesis and tumor growth. Etoposide, on the other hand, works by forming a complex with the enzyme topoisomerase II, which is necessary for DNA replication and transcription. This complexation leads to the inhibition of DNA replication and transcription, ultimately resulting in cell death.
Approved indications
- Metastatic gastric cancer
- Non-small cell lung cancer
Common side effects
- Hemorrhage
- Fatigue
- Nausea
- Vomiting
- Diarrhea
- Anemia
- Thrombocytopenia
- Leukopenia
- Neutropenia
- Anorexia
Key clinical trials
- Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children (PHASE2)
- Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas (PHASE2)
- Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC (PHASE2)
- Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer (PHASE2)
- Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer (PHASE2)
- Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Apatinib and Etoposide capsule CI brief — competitive landscape report
- Apatinib and Etoposide capsule updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI